Hepatitis C Virus E2 Envelope Glycoprotein Induces an Immunoregulatory Phenotype in Macrophages
Young‐Chan Kwon, Keith Meyer, Guangyong Peng, Soumya Chatterjee, Daniel F. Hoft, Ranjit Ray – 14 February 2018 – A comprehensive strategy to control hepatitis C virus (HCV) infection needs a vaccine. Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers. We analyzed the interactions of HCV EnvGPs with human monocyte‐derived macrophages as antigen‐presenting cells.